Product related factors influencing the immunogenicity of...
Haji Abdolvahab, Mohadeseh
Therapeutic interferon beta is the first line treatment of relapsing remitting Multiple Sclerosis. However, despite their success in improving patient wellbeing, all IFNß products encounter a significant problem: immunogenicity. In some patients, IFNß products induce the formation of antidrug antibodies that undermine treatment efficacy and may even lead to treatment failure. These patients not only have a substantial health risk due to failin...